Company Information

Company Profile

Company Profile

Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patient’s own T-cells to express our SPEAR TCRs to target and potentially destroy tumors.

Our wholly-owned pipeline includes SPEAR T-cell therapies targeting ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4), and ADP-A2AFP (AFP), which are being investigated in clinical studies across multiple solid tumor indications. We continue to build a pipeline of further proprietary TCR therapeutic candidates, next-generation treatment options, as well as allogeneic (off-the-shelf) solutions.

We believe our approach will lead to SPEAR T-cells with the potential to significantly impact cancer treatment and the clinical outcomes of cancer patients.

Industry Classifications






Pharmaceutical Preparations (2834)

Adaptimmune at a Glance


Responses in six solid tumor indications demonstrate SPEAR T-cell potential to treat cancer.


The Company aims to launch ADP‑A2M4 for sarcoma in 2022.


Following our June 2020 public offering, we raised approximately $243 million to advance the development of our therapies into and through clinical trials as well as for other general corporate purposes.

As of June 4, 2020

Frequently Asked Questions

Browse our commonly asked investor-related questions

View FAQs

IR Contacts

View investor-related contact information

View IR Contacts